The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...
Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...
Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is ...
The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...
The group of like-named companies that include Novo Holdings and Novo Nordisk—the two tied to a multibillion-dollar buyout of Catalent currently under FTC review—ultimately send proceeds to the Novo ...
Catalent, a leading contract drug manufacturer, issued an open letter Monday to reassure customers that a proposed $16.5 ...
Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...
Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...
FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...
Financial groups and labor unions urge FTC to block Nordisk Foundation's acquisition of Catalent, citing concerns about ...
Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback